LAS VEGAS, January 24, 2018 /PRNewswire/ --
FN Media Group Presents Microcapspeculators.com News Commentary
AfterU.S. Attorney General Jeff Sessions remarks earlier this month, many believe that there could potentially be a federal crackdown on the marijuana industry. Stocks did dive a bit earlier in the month, but they are rising
64% of Americans support full legalization according to an October 2017 Gallop poll. This percentage is even higher for medical marijuana, with 90% of public support. Sales jumped from $1.5B in 2013 to approximately $10B in 2017 according to Arcview Market Research.
Sessions will have a hard time combating such a monetarily successful industry with widespread public support. Undermining the Cole memo may even prove that states no longer need that protection anyway, as it is not long applicable in this day in age.
Let's take a look at some successful cannabis and CBD companies: NightFood Holdings, Inc. (OTC: NGTF), GW Pharmaceuticals plc (NASDAQ: GWPH), INSYS Therapeutics, Inc. (NASDAQ: INSY), Terra Tech Corp. (OTCQX: TRTC), and Medical Marijuana, Inc. (OTC: MJNA).
NightFood Holdings, Inc. (OTC: NGTF)
Market Cap: $16.8M, current share price: $.52
NGTF, the category leading, better-for-you, sleep friendly nighttime snacking company has announced its new subsidiary, MJ Munchies, Inc. The new subsidiary will be responsible for the development of their new line of CBD infused edibles and other cannabis related initiatives. NGTF formed MJ Munchies, Inc. as the company aims to maintain a clear distinction between the NightFood brand and the CBD and marijuana related brands. This is a smart move on NGTF's part as each initiative coming down the pipeline addresses a different consumer segment and different needs. As the Company is projected to undergo major growth with innovative product lines, it is important that they retain their consumer base across all lines of business. Something NGTF is definitely taking seriously.
GW Pharmaceuticals plc (NASDAQ: GWPH)
Market Cap: $3.679B, current share price: $132.50
Despite the current political climate regarding the legality of cannabis in the United States, the biopharmaceutical company, GWPH, is ahead of the game in terms of U.S. patents. The Company's lead candidate, Epidiolex, has had seven years of exclusivity in the U.S. The drug has obtained Orphan Drug Designation in both the U.S. and Europe as GWPH has done an impressive job with their aggressive patent strategies for the CBD-based drug. Some analysts are estimated the drug will reach sales of $800M or $1B.
INSYS Therapeutics, Inc. (NASDAQ: INSY)
Market Cap: $658.383M, current share price: $9.00
INSY, is a commercial-stage specialty pharmaceutical company headquartered in Chandler, Arizona. INSY has recently stated they are taking strategic steps in order to restore stakeholder confidence. The Company is planning to invest $14M in its Texas-based manufacturing facility and have committed to achieving one new drug application (NDA) within a 5-year trajectory. The last quarter of 2017, the FDA granted fast track designation to Insys's cannabidiol oral solution for the treatment of Prader-Willi syndrome.
Terra Tech Corp. (OTCQX: TRTC)
Market Cap: $304.236M, current share price: $.33
Tomorrow, TRTC's CEO Derek Peterson, will be presenting live at 1:00pm EST at the VirtualInvestorConferences.com. The link to access the presentation is https://tinyurl.com/0118prepr. This is a live, interactive online event where investors are asked to join the conversation and ask the featured companies questions with real-time responses. TRTC is a vertically integrated cannabis-focused agriculture company reporting total revenues generated for the third quarter ended September 2017 at $10.1M, compared to $7.0M in the same quarter in 2016. With medical marijuana now legal in 30 states it is becoming increasingly difficult to see any political upside to opposing legalization. The marijuana industry may actually be untouchable by the feds because states have a lot to lose, and will do anything to protect it.
Content Provided By: Microcap Speculators Email: email@example.com Phone: 1-702-720-6310 Website: http://microcapspeculators.com/ For Full Legal Disclaimer Click Here .
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
Media Contact FN Media Group LLC firstname.lastname@example.org +1(954)345-0611
Subscribe to our Free Newsletters!
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...View All